09/28/23 4:15 PMNasdaq : WVE Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D DayPresented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Wave’s best-in-class GalNAc-siRNA capabilities and novel genetic insights from GSK WVE-006 – industry’s first-ever RNA editing clinical candidate – onRHEA-AIneutral
09/25/23 8:30 AMNasdaq : WVE conferencesWave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines ConferenceWave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief ExecutiveRHEA-AIneutral
09/06/23 8:30 AMNasdaq : WVE conferencesWave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceWave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief ExecutiveRHEA-AIneutral
09/05/23 7:30 AMNasdaq : WVE conferencesclinical trialWave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce levels of mutant Z-AAT protein, thereby addressing alpha-1 antitrypsin deficiency-related lungRHEA-AIneutral
08/03/23 7:30 AMNasdaq : WVE earningsWave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business UpdatePreparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate (WVE-006), the industry’s first RNA editing clinical candidate Novel DMD therapeutic candidate (WVE-N531) with best-in-class exon skipping clinical data is on track to enter a potentiallyRHEA-AIneutral
07/27/23 8:30 AMNasdaq : WVE earningsWave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Thursday,RHEA-AIneutral
06/26/23 8:30 AMNasdaq : WVE Wave Life Sciences Joins the Russell 2000® and Russell 3000® IndexesWave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that the company has been added to the small-cap RussellRHEA-AIneutral
05/23/23 7:30 AMNasdaq : WVE clinical trialWave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal DementiaPotent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical benefit compared with placebo; additionally, poly(GP) reductions did not correlate with clinicalRHEA-AIneutral
05/16/23 8:30 AMNasdaq : WVE Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual MeetingPresentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is designed to restore healthy, wild-type AAT protein Best-in-class exon skipping clinical data for WVE-N531RHEA-AIneutral
05/03/23 7:30 AMNasdaq : WVE earningsWave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business UpdateEmerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs Rapidly advancing toward 2023 CTA submissions and first-in-human study for WVE-006, the industry’s first RNA editing clinical candidate Planning for potentiallyRHEA-AIneutral